title: [The effectiveness of intravitreal administration of bevacizumab for choroidal neovascularization in retinal angioid streaks].
abstract: OBJECTIVE
  To investigate the effectiveness of intravitreal administration of bevacizumab (IVB) for choroidal neovascularization (CNV) in retinal angioid streaks (AS).
  
  
  METHODS
  Five eyes of four subjects with CNV in AS were observed for an average followup period of 12 months. The average greatest linear diameter (GLD) of the AS was 4315 microm before treatment. IVB (1.0 mg or 1.25 mg) was performed a total of two times at eight week intervals, and additional bevacizumab was administered whenever exudative changes occurred.
  
  
  RESULTS
  Visual acuity improved in one eye (20%), was maintained in two eyes (40%), and worsened in two eyes (40%). Recurrence of CNV was observed in two eyes (40%). Before treatment, the GLD was 2439, 2844, and 3654 microm in the three eyes in which visual acuity was maintained, and 5803 and 6837 microm in the two eyes with worsened visual acuity. Recurrence of CNV was observed in the two eyes with worsened visual acuity.
  
  
  CONCLUSIONS
  Short-term CNV fibrosis and maintenance of visual acuity were achieved with IVB in cases in which the GLD was less than 3500 microm.
authors.affiliation: Department of Ophthalmology, Ehime University Graduate School of Medicine, Shitsukawa, Toon-shi, Ehime-ken 791-0295, Japan.
authors.forename: Eriko
authors.initials: E
authors.lastname: Noda
authors.forename: Takeshi
authors.initials: T
authors.lastname: Joko
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tasaka
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ohashi
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000793:Angioid Streaks / Q000150:complications*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab